Navigation Links
ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference
Date:9/13/2007

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, ADVENTRX's chief executive officer, is scheduled to present at the ThinkEquity Partners' Fifth Annual Growth Conference on Wednesday, September 19th, 2007 at 2:30 p.m. Pacific Daylight Time, 5:30pm Eastern Daylight Time. The conference takes place in San Francisco at the St. Regis hotel, September 17 -- 20, 2007.

The presentation will be webcast live via the "Investors" section of the Company's web site at http://www.adventrx.com under "Events." The webcast will be available for replay for 14 days and can be accessed through the same link.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the ability to timely enroll subjects in and the results of ADVENTRX's current and anticipated clinical trials; the potential for ADVENTRX's product candidates to receive regulatory approval for one or more indications on a timely basis or at all, and the uncertain process of seeking regulatory approval; the market potential for ADVENTRX's product candidates and ADVENTRX's ability to compete in those markets; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... TEL AVIV, Israel , May 24, 2016   ... on providing physicians with artificial intelligence, real-time decision support tools ... selected to present at the 2016 Israeli Advanced Technology Industries ... part of Israel,s 15th National Life ... to 26th at the David Intercontinental Hotel in ...
(Date:5/23/2016)... Texas (PRWEB) , ... May 23, 2016 , ... The need for blood donations in ... this week by the South Texas Blood & Tissue Center, blood donations are on the ... 30 years, and they are down 21 percent in South Texas in the last four ...
(Date:5/23/2016)... -- Oxitec CEO Hadyn Parry will ... ET before the United States House Committee on Science, Space ... in controlling the spread of the Aedes aegypti ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec has ... Trials in Brazil , Panama ...
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight Institute ... announced the winners for the 2015 Foresight Institute Feynman Prizes. , These ... two categories, one for experiment and the other for theory in nanotechnology. Prof. ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):